Abstracts tagged "Synovial Immune Biology"

Abstract Number: 1744 • 2014 ACR/ARHP Annual Meeting
CD4+ T Cell Subpopulations in Blood and Synovial Fluid Defined By Differential Expression of Integrins
Deepak A. Rao¹, Adam Chicoine², Peter A. Nigrovic³, Soumya Raychaudhuri⁴, Michael B. Brenner⁵ and ACR Authors 2014, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Immunology, Allergy, Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital/Harvard University, Cambridge, MA, ⁴Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁵Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose CD4+ T cells are important mediators of inflammation in rheumatoid arthritis; however, the specific CD4+ T cell populations most important in driving disease pathology…
Abstract Number: 2805 • 2013 ACR/ARHP Annual Meeting
Synovial Explant Inflammatory Mediator Production Is Associated With Synovitis While Not With Bone Marrow Edema In Rheumatoid Arthritis: A Cross Sectional Study
Martin Andersen¹, Mikael Boesen², Karen Ellegaard¹, Robin Christensen³, Kalle Söderström⁴, Søren Torp-Pedersen¹, Bente Danneskiold-Samsøe¹, Else Marie Bartels⁵, Nina Vendel⁶, Niels H. Søe⁷, Pieter Spee⁸, Ulrik GW Mørch⁹, Lars Karlsson⁴ and Henning Bliddal¹⁰, ¹Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ²Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Department of Radiology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiskberg, Denmark, ³Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ⁴Biopharmaceutical Research Unit, Novo Nordisk, Translational Immunology, Biopharmaceutical Research Unit, Måløv, Novo Nordisk, Denmark, Måløv, Denmark, ⁵Rheumatology, Copenhagen University Hospital,Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ⁶Department of Anaesthesiology, Intensive Care and Operations, Gentofte University Hospital, Denmark, Hellerup, Denmark, ⁷Department of Orthopedics, Section of Hand Surgery, Gentofte University Hospital, Department of Orthopedics, Section of Hand Surgery, Gentofte University Hospital, Denmark, Hellerup, Denmark, ⁸Biopharmaceutical Research Unit Novo Nordisk, Translational Immunology, Biopharmaceutical Research Unit, Måløv, Novo Nordisk, Denmark, Måløv, Denmark, ⁹Biomarkers, Søborg, Novo Nordisk, Denmark, Biomarkers, Søborg, Novo Nordisk, Denmark, Søborg, Denmark, ¹⁰The Parker Institute, Copenhagen, Denmark
Background/Purpose: Synovitis and bone damage may represent two distinct but overlapping pathological processes in rheumatoid arthritis (RA). Whereas the bulk of synovial cells contribute to…
Abstract Number: 1903 • 2013 ACR/ARHP Annual Meeting
PIK3CD Overexpression In The Synovial Membrane Of Rheumatoid Arthritis Patients Is Associated With Response To Anti-TNF Therapy
Antonio Julià¹, Gabriela Ávila¹, Raquel Celis², Raimon Sanmarti³, Julio Ramirez⁴, Sara Marsal¹ and Juan D. Cañete³, ¹Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁴Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: The mechanisms by which Rheumatoid Arthritis (RA) patients do not respond to TNF blockade are still poorly characterized. The goal of this study is…
Abstract Number: 1794 • 2013 ACR/ARHP Annual Meeting
The Jak Inihibitor Tofacitinib Suppresses Synovial Jak-Stat Signalling In Rheumatoid Arthritis
D. L Boyle¹, N. Wei², A. K. Singhal³, D. R. Mandel⁴, P Mease⁵, A. Kavanaugh⁶, R. Shurmur⁷, J. Hodge⁸, Z. Luo⁹, S. Krishnaswami¹⁰, D. Gruben⁹, S. H. Zwillich⁹, K. Soma⁹, J. D. Bradley⁹ and G. S. Firestein¹¹, ¹Div of Rheum, UCSD School of Medicine, La Jolla, CA, ²Arthritis Treatment Center, Frederick, MD, ³Southwest Rheumatology Research LLC, Mesquite, TX, ⁴Office of David R Mandel MD, Inc., Mayfield Village, OH, ⁵Seattle Rheumatology Associates, Seattle, WA, ⁶UCSD School of Medicine, La Jolla, CA, ⁷Associated Internal Medicine Specialists, Battle Creek, MI, ⁸Pfizer Inc, Collegeville, PA, ⁹Pfizer Inc, Groton, CT, ¹⁰Clinical Pharmacology, Pfizer Inc, Groton, CT, ¹¹Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Tofacitinib is a novel oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The specific JAK-STAT (signal transducer and activator of…
Abstract Number: 1653 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Synovial IL-21+CD4+ T Cells Specifically Induce Matrix Metalloproteinase Production By Fibroblast-Like Synoviocytes
Maria C. Lebre¹, Pedro L. Vieira², Saïda Aarrass¹, Thomas Newsom-Davis², Paul Peter Tak³ and Gavin R. Screaton², ¹Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Immunology, Imperial College London, London, United Kingdom, ³Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: IL-21 is a cytokine produced by activated CD4+ T cells and T follicular helper cells (TFh) that has been implicated in several autoimmune diseases…
Abstract Number: 1149 • 2013 ACR/ARHP Annual Meeting
Phenotypic and Molecular Profile Of Innate Lymphoid Cells In Chronic Synovial Inflammation
Hulda S. Hreggvidsdottir^1,2, Maureen C. Turina¹, Troy Noordenbos^1,3, Marius Munneke⁴, Charlotte Peters², Jochem Bernink², Jenny Mjosberg⁵, Dominique L. Baeten⁶ and Hergen Spits², ¹Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Tytgat Institute for Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Department of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Department of Hematology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Innate lymphoid cells (ILCs) represent a novel family of effector and regulatory cells in innate immunity and tissue remodelling. The family comprises several phenotypically…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].